Kelly Monaghan

Rare disease research and development is complex. But we can take steps now that will create a better future. Below are the 10 recommendations from our recent report with Genetic Alliance UK to help #ChangeTheRareFuture for those living with rare conditions. Find the full report here: https://lnkd.in/enrFifAs

71

NHS Wales has launched its new Healthcare Science Framework, mapping career pathways and opportunities in the profession. The IBMS contributed to the development of the Pathology and Genomics pathway to ensure it reflects the realities of biomedical science in Wales. You can read more about the framework and how it supports biomedical scientists here: https://bit.ly/4fHgkBi

55

Today we’re pleased to share our Clinical Academics Summit statement, signed by over 40 organisations 🤝 An alarming decline in clinical academic posts threatens the UK’s ability to develop new treatments and remain a global leader in health research ⚠️ Clinical academics are vital in connecting research and patient care – shaping research priorities through frontline experience and bringing new scientific discoveries straight to patients 🧑‍⚕️ ✨ Earlier this year, we convened leaders from universities, research funders, industry partners, the NHS and Government at a summit to commit to action to help reverse this trend. The statement of ambition and intent seeks to address the OSCHR reports’ recommendation to increase the number of permanent clinical academic posts, year-on-year. Our summit attendees committed to five priorities: 1️⃣ Raise awareness of the benefits and opportunities in clinical academia 2️⃣ Prioritise funding for new posts 3️⃣ Champion clinical research as central to care delivery 4️⃣ Build local partnerships across academia, industry, funders and the NHS 5️⃣ Tackle barriers faced by underrepresented groups including nurses, midwives, allied health professionals, ethnic minorities and women 📖 Read the full statement: https://lnkd.in/eU4PiVbS #ClinicalAcademics #HealthResearch #MedicalResearch

122

3 Comments

We are delighted to announce another step forward in bringing innovative science out of the lab and into the world with the launch of Brigid Bio, a new spin-out developing treatments that use antibodies to fight dangerous fungal infections - especially those that are resistant to current medicines. Founded by the University's Professor Carol Munro, a medical mycology expert in the Aberdeen Fungal Group, with Dr Soumya Palliyil and Professor Andy Porter, innovators in antibody generation who lead the Scottish Biologics Facility, the technology has the potential to transform the healthcare of critically ill patients around the world. http://abdn.io/1zT

260

8 Comments

'We need to move with the times' - Matthew Durdy, Chief Executive, Cell and Gene Therapy Catapult.   In this Pink Sheet interview, Matthew Durdy, CGT Catapult, discusses how recent changes in UK drug regulations could impact the #cell and #gene therapy industry, and how the Medicines and Healthcare products Regulatory Agency (MHRA)'s new reforms in decentralised manufacturing are a positive signal for the UK's #CellTherapy ecosystem.   Read the interview: https://lnkd.in/eK4AR8BG   #ATMPs #AdvancedTherapies Citeline

47

3 Comments